Analysis of riluzole’s profile of use in a central hospital in Lisbon

Ana Paróla, Fátima da Silva Mousinho de Palhares Falcão, Helena Farinha, André Caetano, Luís Santos, Elmira Medeiros, Miguel Viana-Baptista

Research output: Contribution to journalArticle

6 Downloads (Pure)

Abstract

Purpose: Riluzole is indicated to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS). Clinical studies have shown that this drug prolongs survival, defined as living patients who are not intubated for mechanical ventilation and without tracheotomy. The purpose of this study is to characterize riluzole’s use as well as the user population in order to contribute to a rational and safe use. Patients and methods: Descriptive, observational, retrospective study describing and characterizing the use of riluzole in ALS patients between July 2006 and December 2016 conducted in a Lisbon’s Central Hospital. Results: Over the course of the study period, 77 patients with different phenotypes of ALS received riluzole. The majority of patients (63%, n=49) were male. The median survival was 10.1 months, but 12 patients (16%) remained on therapy for more than 3 years; 65% of patients were lost to follow-up. The mean adherence rate was 91.2%, and the median adherence rate was 99.3%. One patient discontinued therapy due to gastrointestinal intolerance. Dyspnea and cough were the most common side effects, with roughly one third of patients experiencing each, followed by asthenia and hepatic effects. Conclusion: Despite the extended enrollment period, only 77 patients met the criteria for study inclusion. Nonetheless, statistical data regarding our population is in accordance with reported international data. High adherence rates were observed, but 14% of patients discontinued riluzole. In such cases, assessment by a multidisciplinary team is warranted.

Original languageEnglish
Pages (from-to)2357-2361
Number of pages5
JournalPATIENT PREFERENCE AND ADHERENCE
Volume12
DOIs
Publication statusPublished - 2018

Fingerprint

Riluzole
tolerance
inclusion
drug
Amyotrophic Lateral Sclerosis
Artificial Respiration
Asthenia
Tracheotomy
Survival
Lost to Follow-Up
Cough
Dyspnea
Population
Observational Studies
Retrospective Studies
Phenotype
Liver
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adherence rate
  • Amyotrophic lateral sclerosis
  • Drug interactions
  • Riluzole
  • Safety profile

Cite this

Paróla, Ana ; de Palhares Falcão, Fátima da Silva Mousinho ; Farinha, Helena ; Caetano, André ; Santos, Luís ; Medeiros, Elmira ; Viana-Baptista, Miguel. / Analysis of riluzole’s profile of use in a central hospital in Lisbon. In: PATIENT PREFERENCE AND ADHERENCE. 2018 ; Vol. 12. pp. 2357-2361.
@article{ae6f4c3a491c49f7b9a1208552ee1a80,
title = "Analysis of riluzole’s profile of use in a central hospital in Lisbon",
abstract = "Purpose: Riluzole is indicated to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS). Clinical studies have shown that this drug prolongs survival, defined as living patients who are not intubated for mechanical ventilation and without tracheotomy. The purpose of this study is to characterize riluzole’s use as well as the user population in order to contribute to a rational and safe use. Patients and methods: Descriptive, observational, retrospective study describing and characterizing the use of riluzole in ALS patients between July 2006 and December 2016 conducted in a Lisbon’s Central Hospital. Results: Over the course of the study period, 77 patients with different phenotypes of ALS received riluzole. The majority of patients (63{\%}, n=49) were male. The median survival was 10.1 months, but 12 patients (16{\%}) remained on therapy for more than 3 years; 65{\%} of patients were lost to follow-up. The mean adherence rate was 91.2{\%}, and the median adherence rate was 99.3{\%}. One patient discontinued therapy due to gastrointestinal intolerance. Dyspnea and cough were the most common side effects, with roughly one third of patients experiencing each, followed by asthenia and hepatic effects. Conclusion: Despite the extended enrollment period, only 77 patients met the criteria for study inclusion. Nonetheless, statistical data regarding our population is in accordance with reported international data. High adherence rates were observed, but 14{\%} of patients discontinued riluzole. In such cases, assessment by a multidisciplinary team is warranted.",
keywords = "Adherence rate, Amyotrophic lateral sclerosis, Drug interactions, Riluzole, Safety profile",
author = "Ana Par{\'o}la and {de Palhares Falc{\~a}o}, {F{\'a}tima da Silva Mousinho} and Helena Farinha and Andr{\'e} Caetano and Lu{\'i}s Santos and Elmira Medeiros and Miguel Viana-Baptista",
year = "2018",
doi = "10.2147/PPA.S167861",
language = "English",
volume = "12",
pages = "2357--2361",
journal = "PATIENT PREFERENCE AND ADHERENCE",
issn = "1177-889X",
publisher = "Dove Medical Press",

}

Analysis of riluzole’s profile of use in a central hospital in Lisbon. / Paróla, Ana; de Palhares Falcão, Fátima da Silva Mousinho; Farinha, Helena; Caetano, André; Santos, Luís; Medeiros, Elmira; Viana-Baptista, Miguel.

In: PATIENT PREFERENCE AND ADHERENCE, Vol. 12, 2018, p. 2357-2361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analysis of riluzole’s profile of use in a central hospital in Lisbon

AU - Paróla, Ana

AU - de Palhares Falcão, Fátima da Silva Mousinho

AU - Farinha, Helena

AU - Caetano, André

AU - Santos, Luís

AU - Medeiros, Elmira

AU - Viana-Baptista, Miguel

PY - 2018

Y1 - 2018

N2 - Purpose: Riluzole is indicated to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS). Clinical studies have shown that this drug prolongs survival, defined as living patients who are not intubated for mechanical ventilation and without tracheotomy. The purpose of this study is to characterize riluzole’s use as well as the user population in order to contribute to a rational and safe use. Patients and methods: Descriptive, observational, retrospective study describing and characterizing the use of riluzole in ALS patients between July 2006 and December 2016 conducted in a Lisbon’s Central Hospital. Results: Over the course of the study period, 77 patients with different phenotypes of ALS received riluzole. The majority of patients (63%, n=49) were male. The median survival was 10.1 months, but 12 patients (16%) remained on therapy for more than 3 years; 65% of patients were lost to follow-up. The mean adherence rate was 91.2%, and the median adherence rate was 99.3%. One patient discontinued therapy due to gastrointestinal intolerance. Dyspnea and cough were the most common side effects, with roughly one third of patients experiencing each, followed by asthenia and hepatic effects. Conclusion: Despite the extended enrollment period, only 77 patients met the criteria for study inclusion. Nonetheless, statistical data regarding our population is in accordance with reported international data. High adherence rates were observed, but 14% of patients discontinued riluzole. In such cases, assessment by a multidisciplinary team is warranted.

AB - Purpose: Riluzole is indicated to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS). Clinical studies have shown that this drug prolongs survival, defined as living patients who are not intubated for mechanical ventilation and without tracheotomy. The purpose of this study is to characterize riluzole’s use as well as the user population in order to contribute to a rational and safe use. Patients and methods: Descriptive, observational, retrospective study describing and characterizing the use of riluzole in ALS patients between July 2006 and December 2016 conducted in a Lisbon’s Central Hospital. Results: Over the course of the study period, 77 patients with different phenotypes of ALS received riluzole. The majority of patients (63%, n=49) were male. The median survival was 10.1 months, but 12 patients (16%) remained on therapy for more than 3 years; 65% of patients were lost to follow-up. The mean adherence rate was 91.2%, and the median adherence rate was 99.3%. One patient discontinued therapy due to gastrointestinal intolerance. Dyspnea and cough were the most common side effects, with roughly one third of patients experiencing each, followed by asthenia and hepatic effects. Conclusion: Despite the extended enrollment period, only 77 patients met the criteria for study inclusion. Nonetheless, statistical data regarding our population is in accordance with reported international data. High adherence rates were observed, but 14% of patients discontinued riluzole. In such cases, assessment by a multidisciplinary team is warranted.

KW - Adherence rate

KW - Amyotrophic lateral sclerosis

KW - Drug interactions

KW - Riluzole

KW - Safety profile

UR - http://www.scopus.com/inward/record.url?scp=85058804530&partnerID=8YFLogxK

U2 - 10.2147/PPA.S167861

DO - 10.2147/PPA.S167861

M3 - Article

VL - 12

SP - 2357

EP - 2361

JO - PATIENT PREFERENCE AND ADHERENCE

JF - PATIENT PREFERENCE AND ADHERENCE

SN - 1177-889X

ER -